Sonnet biotherapeutics provides fiscal year 2023 third quarter business and earnings update

Combination study of son-1010 with roche's atezolizumab (tecentriq®) has been initiated in australia first son-1010 phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissue early safety data from the son-080 trial in cipn is expected after the study's data safety monitoring board (dsmb) convenes, prior to calendar year end collaboration with janssen,where in vitro and in vivo efficacy of son-1010, son-1210, and son-1410 are being evaluated in combination with certain janssen cell therapy assets, remains ongoing princeton, nj / accesswire / august 14, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended june 30, 2023 and provided a business update. "sonnet continues to successfully forge ahead with our pipeline development," said pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking